Daily FNArena News - Australia

Commonwealth Bank is moving back to being a retail and business bank and brokers welcome the potential for capital management down the track.

Unibail-Rodamco-Westfield has reiterated 2018 earnings guidance, with dilution from asset sales countering the accretion from the acquisition of Westfield.

The price ResMed is paying for MatrixCare is rich, although brokers accept the deal will significantly expand its offering in home health data analytics.

Another difficult year looms for Westpac and, while mortgage re-pricing should boost first half performance, slower wealth revenues and further customer remediation are likely to weigh.

After a soft FY18 result Orica expects ammonium nitrate volumes will improve. However, uncertainties over the Burrup plant weigh on the outlook.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

As issues surrounding Australian housing credit growth and tightening lending standards continue to dog the banks, National Australia Bank’s FY18 results indicate a weighting to the commercial sector stands it in good stead.

ANZ Bank is executing well on its strategy to address the challenging financial and regulatory environment and brokers were relieved there were no negative surprises in the FY18 result.

Western Areas performed to expectations over the September quarter and the outlook now centres on the development plans for the Odysseus mine.